An intensive BP reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and older with untreated hypertension.

For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial.

Implantable cardioverter-defibrillator therapy in patients with Brugada syndrome is effective for prevention of fatal arrhythmias.

A scientific statement regarding risk-based primary prevention of heart failure has been published by the American Heart Association.

Metabolic syndrome (MetS) and its individual components are associated with an increased risk for young-onset dementia (YOD).

The FDA has extended the review period for the NDA for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. Drug ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Both dual use of traditional and e-cigarettes and exclusive cigarette use are associated with higher toxicant exposure than exclusive e-cigarette use.

The Food and Drug Administration (FDA) has cleared the Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD).

Exposure to antihypertensives, NSAIDs, and statins showed a strong correlation with older Parkinson disease age at onset, while smoking and family history, however, correlated with younger age at ...

Average and brisk walking pace are associated with a decreased risk for all cardiac arrhythmias, atrial fibrillation, and other arrhythmias.